FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis

WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development program. On September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of...